Zimmer Biomet Holdings, Inc. $ZBH Holdings Lifted by Envestnet Asset Management Inc.

Key Points

• Envestnet Asset Management increased its Zimmer Biomet stake by 4% in the second quarter to 308,571 shares valued at approximately $26.6 million. Institutional investors collectively own 88.89% of the company.
• Analyst sentiment remains cautious, with a consensus “Hold” rating and an average price target of $103.00; six analysts rate the stock Buy, 14 Hold, and two Sell.
• Zimmer Biomet exceeded quarterly expectations with $2.07 in EPS and $2.18 billion in revenue, while revenue rose 4.8% year over year. The company also declared a quarterly dividend of $0.24 per share, representing a 1.0% yield.

Envestnet Asset Management Inc. boosted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 4.0% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 308,571 shares of the medical equipment provider's stock after acquiring an additional 11,783 shares during the period. Envestnet Asset Management Inc. owned 0.16% of Zimmer Biomet worth $26,565,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Main Management ETF Advisors LLC raised its stake in shares of Zimmer Biomet by 1.0% during the 4th quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the medical equipment provider's stock valued at $986,000 after purchasing an additional 112 shares during the period. Citizens National Bank Trust Department lifted its stake in Zimmer Biomet by 17.6% during the first quarter. Citizens National Bank Trust Department now owns 941 shares of the medical equipment provider's stock worth $85,000 after purchasing an additional 141 shares during the last quarter. Leonteq Securities AG boosted its stake in Zimmer Biomet by 5.3% in the first quarter. Leonteq Securities AG now owns 3,062 shares of the medical equipment provider's stock worth $277,000 after buying an additional 153 shares in the last quarter. Valeo Financial Advisors LLC boosted its stake in Zimmer Biomet by 1.6% in the second quarter. Valeo Financial Advisors LLC now owns 11,176 shares of the medical equipment provider's stock worth $962,000 after buying an additional 175 shares in the last quarter. Finally, Corbyn Investment Management Inc. MD grew its position in Zimmer Biomet by 0.5% during the first quarter. Corbyn Investment Management Inc. MD now owns 34,050 shares of the medical equipment provider's stock valued at $3,079,000 after acquiring an additional 183 shares during the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on ZBH shares. Zacks Research raised shares of Zimmer Biomet from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 25th. Wall Street Zen lowered shares of Zimmer Biomet from a "buy" rating to a "hold" rating in a report on Saturday, August 8th. Sanford C. Bernstein lifted their price objective on Zimmer Biomet from $91.00 to $93.00 and gave the stock a "market perform" rating in a report on Thursday, August 6th. Weiss Ratings upgraded shares of Zimmer Biomet from a "hold (c-)" rating to a "hold (c)" rating in a report on Monday, September 14th. Finally, UBS Group reaffirmed a "buy" rating and set a $120.00 price target on shares of Zimmer Biomet in a research report on Thursday, August 6th. Six investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Zimmer Biomet currently has a consensus rating of "Hold" and an average price target of $103.00.

Insider Buying and Selling

In other Zimmer Biomet news, insider Kevin R. Thornal sold 5,691 shares of Zimmer Biomet stock in a transaction on Friday, September 11th. The stock was sold at an average price of $92.95, for a total transaction of $528,978.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Chad Phipps sold 3,000 shares of the business's stock in a transaction on Friday, September 4th. The stock was sold at an average price of $98.35, for a total value of $295,050.00. Following the completion of the sale, the insider directly owned 65,231 shares in the company, valued at $6,415,468.85. This trade represents a 4.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 1.28% of the stock is owned by company insiders.

Zimmer Biomet Stock Up 0.5%

Shares of Zimmer Biomet stock opened at $91.51 on Tuesday. Zimmer Biomet Holdings, Inc. has a 1 year low of $79.12 and a 1 year high of $106.88. The firm has a market cap of $17.45 billion, a price-to-earnings ratio of 22.26, a PEG ratio of 1.72 and a beta of 0.47. The company has a 50-day moving average of $96.27 and a 200 day moving average of $91.25. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The business had revenue of $2.18 billion for the quarter, compared to analyst estimates of $2.13 billion. During the same quarter in the previous year, the firm posted $2.07 earnings per share. Zimmer Biomet's quarterly revenue was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Zimmer Biomet's dividend payout ratio (DPR) is 23.36%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc NYSE: ZBH is a medical technology company that develops, manufactures and markets products designed to treat musculoskeletal conditions. Its portfolio includes orthopedic implants and related systems for hip, knee, shoulder and other joint replacements, as well as products used in sports medicine, extremity care and trauma procedures.

The company also provides robotic- and computer-assisted surgical technologies, digital solutions and other tools intended to support orthopedic procedures and patient care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.